Top Markets
Coin of the day
AstraZeneca PLC AstraZeneca PLC

AstraZeneca PLC

AZN
Kedudukan dalam Saham #105
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery,... AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Harga Saham
$193.62
Modal Pasaran
$150.08B
Perubahan (1 hari)
2.76%
Perubahan (1 tahun)
184.69%
Negara
GB
Perdagangan AstraZeneca PLC (AZN)

Kategori

Sejarah dividen untuk AstraZeneca PLC (AZN)
AstraZeneca PLC (simbol saham: AZN) telah membuat sejumlah 67 pembayaran dividen.
Jumlah semua dividen (disesuaikan untuk pemecahan saham): $33.24
Hasil dividen (TTM): 0.0161
Pembayaran dividen untuk AstraZeneca PLC (AZN) dari 1993 hingga 2026
Pembayaran dividen tahunan
Tahun Dividen (diselaraskan untuk pemecahan saham) Ubah
2026 (TTM) $2.17 38.88%
2025 $1.57 6.10%
2024 $1.48 1.72%
2023 $1.45 0.00%
2022 $1.45 3.57%
2021 $1.40 0.00%
2020 $1.40 0.00%
2019 $1.40 0.00%
2018 $1.40 0.00%
2017 $1.40 0.00%
2016 $1.40 0.00%
2015 $1.40 0.00%
2014 $1.40 0.00%
2013 $1.40 -1.75%
2012 $1.43 5.56%
2011 $1.35 12.03%
2010 $1.21 15.31%
2009 $1.05 10.00%
2008 $0.95 8.57%
2007 $0.875 24.11%
2006 $0.705 37.56%
2005 $0.5125 22.75%
2004 $0.4175 7.46%
2003 $0.3885 -0.13%
2002 $0.389 0.00%
2001 $0.389 -57.97%
2000 $0.9255 205.45%
1999 $0.303 -23.77%
1998 $0.3975 11.38%
1997 $0.3569 44.49%
1996 $0.247 -13.97%
1995 $0.2871 10.47%
1994 $0.2599 169.33%
1993 $0.0965 0.00%
Senarai semua pembayaran dividen
Tahun Dividen Ubah
2026 (TTM) $2.17 38.88%
2025 $1.57 6.10%
2024 $1.48 3.15%
2023 $1.43 0.70%
2022 $1.42 2.16%
2021 $1.39 0.00%
2020 $1.39 -0.71%
2019 $1.40 0.00%
2018 $1.40 0.00%
2017 $1.40 0.00%
2016 $1.40 -40.43%
2015 $2.35 -16.07%
2014 $2.80 0.00%
2013 $2.80 -1.75%
2012 $2.85 5.56%
2011 $2.70 12.03%
2010 $2.41 15.31%
2009 $2.09 10.00%
2008 $1.90 8.57%
2007 $1.75 24.11%
2006 $1.41 37.56%
2005 $1.03 22.75%
2004 $0.835 7.46%
2003 $0.777 -0.13%
2002 $0.778 0.00%
2001 $0.778 -57.97%
2000 $1.85 205.45%
1999 $0.606 -66.68%
1998 $1.82 -15.04%
1997 $2.14 44.47%
1996 $1.48 -13.99%
1995 $1.72 10.52%
1994 $1.56 169.26%
1993 $0.579 0.00%
Pembayaran dividen untuk syarikat serupa atau pesaing
Syarikat Jumlah pembayaran dividen Negara
215.00%
US
225.00%
US
53.00%
US
32.00%
CH
223.00%
US